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Abstract
The human immunodeficiency virus type 1 (HIV-1) characteristics associated with mother-to-child transmission
(MTCT) are still poorly understood. We studied a cohort of 30 mothers from Rwanda infected with HIV-1
subtype A or C viruses of whom seven infected their children either during gestation or soon after birth. CD4
counts and viral load did not significantly differ between nontransmitting mother (NTM) versus transmitting
mother (TM) groups. In contrast to earlier studies we not only analyzed and compared the genotypic charac-
teristics of the V1-V5 region of the gp120 envelope of viruses found in TM and their infected children, but also
included data from the NTM. No differences were found with respect to length and number of potential N-
glycosylation sites (PNGS) in the V1-V2 and the V1-V5 region. We identified that viruses with a PNGS on
positions AA234 and AA339 were preferably transmitted and that viruses with PNGS-N295 showed a disad-
vantage in transmission. We also showed that the frequency of PNGS-N339 in the viruses of TM and infected
children was significantly higher than the frequency in NTM in our cohort and in viruses undergoing sexual
transmission while the frequency of PNGS-N295 in children was significantly lower than the frequency in TM
and acute horizontal infections. Collectively, our results provide evidence that the presence of the PNGS-N339
site and absence of the PNGS-N295 site in the gp120 envelope confers an advantage to HIV-1 when considering
MTCT.
Introduction
Transmission of HIV-1 from mother to child accountsfor a significant proportion of transmissions in those
countries where antiviral therapy is still limited. For example,
in 2009 over 370,000 children less than 15 years of age were
infected with human immunodeficiency virus, with the vast
majority via mother-to-child transmission (MTCT) (www
.unaidstoday.org). Known maternal risk factors associated
with MTCT are high plasma viral loads, low CD4 T cell
numbers coinciding with advanced maternal immune defi-
ciency, and prolonged labor. In the absence of antiretroviral
therapy approximately a third of mothers will transmit HIV-1
to their children during pregnancy, labor, or through breast-
feeding, and at equal ratios.1
A number of studies focused on analyzing the molecular
characteristics of viruses that get transmitted, either through
MTCT or sexual intercourse, show that the majority of infec-
tions are characterized by the presence of a highly homoge-
neous viral population.2 These viruses are predicted to
exclusively utilize the CCR5 coreceptor (termed R5 viruses)
for infection even when the mothers are shown to carry
CXCR4 using variants (termed R5/X4 or X4 viruses),3 indic-
ative of a strong R5 selection pressure. This is somewhat
surprising in children given the predominance of CXCR4
expressing naive CD4+ lymphocytes in the circulation, a
consequence of limited antigen exposure.4,5
Virus selection during MTCT may be influenced by the
binding affinity of the gp120 envelope glycoprotein to a
number of cell receptors. A higher affinity for the CD4
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receptor or the CCR5 coreceptor may be of advantage for the
infecting virus particle. A low net charge within the V3 vari-
able loop of gp120 and the presence of a potential N linked
glycosylation site (PNGS) on position 301 of the V3 loop6–8 are
variables that have been associated with higher CCR5 affinity
and being the variants preferentially transmitted.9,10
InMTCT the HIV-1 variants transmitted to children tend to
be more resistant to maternal plasma at time of delivery in
comparison to viruses from the mother.11,12 Some studies
suggest that the properties and function of maternal anti-
bodies (Abs) in MTCT can prevent perinatal transmission or
mediate viral selection.13 A number of gp120 envelope char-
acteristics have been associated with resistance against neu-
tralizing Abs, such as the V1-V2 region of the envelope, which
has been postulated to regulate neutralization sensitivity by
occluding conserved epitopes such as the CD4 and/or cor-
eceptor binding sites.14,15 The V1-V2 length of subtype C
viruses has been shown to positively correlate with resistance
to broadly cross-neutralizing sera.16–21
It has been postulated that HIV-1 transmission can be en-
hanced by binding of the gp120 glycan moiety to the C-type
lectin DC-SIGN, which is expressed at high levels on imma-
ture dendritic cells (DCs) and facilitates infection of CD4 + T
lymphocytes either locally or in distal lymph nodes.22–24 DC-
SIGN expressed by a subset of B cells in the tonsils and blood
may also contribute to the infection of CD4 + lymphocytes.25 If
this mode of transmission plays a role in MTCT, selection of
the transmitting virus may be driven by more efficient bind-
ing of the virus to DC-SIGN.
Here we study a group of 30 pregnant mothers from
Rwanda infected with either HIV-1 subtype A or C viruses of
whom seven transmitted virus to their children. No correla-
tion was identified between viral loads or CD4 + lymphocyte
counts for transmitting mother (TM) or nontransmitting mo-
ther (NTM). We analyzed the gp120 envelope sequences for
TM, NTM, and infected children. From this analysis we
identified two potential glycosylation sites, PNGS-N234 and
PNGS-N339, which were associated with viruses that are
preferentially transmitted from mother to child and a disad-
vantage in transmission for viruses with PNGS-N295.
Materials and Methods
Study population
This is a subanalysis as part of a clinical study performed in
Kigali, Rwanda as previously described.26 In brief, the study
is composed of a group of 30 HIV-1-infected women from
Rwanda and their children. Plasma samples were obtained
from both mothers and children at time of delivery and at
week 16. Seven children tested HIV-1 positive at 16 weeks
after delivery. All the women were given a single dose of
nevirapine at the start of labor to reduce peripartum trans-
mission of HIV-1. All children were breastfed during the 16-
week period.
Viral load and CD4 + cell count assessment
Blood plasma samples were analyzed for HIV-1 viral loads
using the Roche diagnostics RNA PCR quantification assay
version 1.5, with a lower limit of detection of 400 copies/ml.
Immunologic testing of mothers was performed in two labo-
ratories (National HIV/AIDS Reference Laboratory, Kigali,
Rwanda and the Joint Clinical Research Center JCRC, Kam-
pala, Uganda).
HIV-1 RNA extraction
HIV-1 RNA was isolated from blood plasma samples ac-
cording to the method of Boom et al.27
Children’s infection status at birth and week 16
Plasma samples taken at birth were tested in a reverse
transcriptase polymerase chain reaction (RT-PCR) amplifica-
tion assay covering the HIV-1 gp120 V3 region. Initially, viral
RNA was converted to cDNA using Superscript III Reverse
Transcriptase (Invitrogen) and the 3¢ primer V3Not (GCG
CGG CCG CCC CCT CTA CAA TTA AAA CTG TG), fol-
lowed by PCR using Taq DNA Polymerase (Roche), 3¢ primer
3¢ V3Not and 5¢ primer 5¢ V3Not (GCG CGG CCG CAC AGT
ACA ATG TAC ACA TGG). A nested PCR was subsequently
performed using 5¢ primer 5¢ KSI (ATA AGC TTG CAG TCT
AGC AGA AGA AGA) and 3¢ primer 3¢ KSI (ATG AAT TCT
GGG TCC CCT CCT GAG GA) and the PCR product was
analyzed by agarose/ethidium bromide electrophoreses. At
week 16 the children’s HIV-1 infection status was determined
using standard viral load assessment as described above.
Amplification of the V1-V5 envelope region
To amplify the V1-V5 envelope region viral RNA was con-
verted into cDNA using the Superscript III Reverse Tran-
scriptase Kit (Invitrogen) and 3¢ primer A1262 (CTG ACG
GTA CAG GCC AGA CAA TTA TTG TC) followed by a PCR
using the Expand Long Template PCR system (Roche), ac-
cording to themanufacturer’s instructions. For the first PCR 5¢
primer A1053 (GAA AGA GCA GAA GAC AGT GGC AAT
GA) and 3¢ primer A1262 were used, and for the second PCR
the 3¢ primer was A1322 (TCT TGG GAG CAG CAG GAA
GCA C) and the 5¢ primer was A0358 (GAG GAT ATA ATC
AGT TTA TGG GA).
Sequencing and analysis
PCR products were sequenced using the ABI PRISM Big
Dye Terminator 1.1 Cycle Sequencing Kit and theABI 3730 XL
DNA Analyzer (Applied Biosystems). Sequences were as-
sembled using the CodonCodeAligner program (CodonCode
Corporation). Alignments were performed taking the trans-
lation codons into account and the sequences were translated
into amino acids using the BioEdit program (Ibis Ther-
apeutics). Analysis of the amplified region was performed
utilizing the neighbor-joining (N-J) method of MEGA version
4. Positions containing an alignment gap were included for
pairwise sequence analysis.
Subtype determination
To determine HIV-1 subtype the V1-V5 envelope PCR
products were sequenced using primers 5¢ A0385 (GAG GAT
ATA ATC AGT TTA TGG GA), 3¢ A1322 (TCT TGG GAG
CAG CAG GAA GCA C), 5¢ A1360 (GAG CCA ATT CCY
ATACAT TAT TG), and 3¢A1191 (ATGGGAGGGGCATAC
ATTGC). The Subtype Reference Alignments of the LosAlamos
Database (www.hiv.lanl.gov/content/sequence/NEWALIGN/
align.htm) year 2005 were used as reference sequences.
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Cloning and sequence analysis
V1-V5 envelope PCR products were cloned into the pCRII-
TOPO vector (Invitrogen). For each subject and time point
between 5 and 15 clones were sequenced using the primers 5¢
SP6 (ATT TAG GTG ACA CTA TAG), 3¢ T7 (TAA TAC GAC
TCA CTA TAG G), 5¢ A1360, and 3¢ A1191. The number of
PNGS was determined using the tool N-GlycoSite of the
HIV sequence Database (http://www.hiv.lanl.gov/content/
sequence/GLYCOSITE/glycosite.html). The mean intrapatient
diversity was calculated with the use of MEGA version 4. The
amino acid length and number of PNGS of the viral envelopes
were compared using GraphPad Prism version 5.00 using the
Mann–Whitney test, with p-values <0.05 being considered
statistically significant. The overall V3 net positive charge was
calculated by counting the number of positive charged amino
acid residues R and K and the number of negative charged
amino acid residues D and E being subtracted.28
Direct sequencing of the C2-C3 region
To expand the groupofNTM for comparison of the frequency
of PNGS-N295 and PNGS-N339 we performed direct sequenc-
ing on theV1-V5 envelopePCRproducts of 10 additionalmothers
encompassing amino acids 245 to 370 (HXB2 numbering) using
5¢ primer (GCG CGG CCG CAC AGT ACA ATG TAC ACA
TGG) and 3¢ primer (AT TTC TAA GTC CCC TCC TGA).
Comparison of the frequency of PNGS-N295
and PNGS-N339
The percentages of glycosylation on pos. AA295 and
AA339 (HXB2 numbering) for subtype A and C were calcu-
lated separately for the envelope sequences from the group of
NTM, children infected in uterine (C2),29 children infected by
breastfeeding (C3),30 breastfeeding TM (TM2),31 acute hori-
zontal infections (contr.1),32–34 and a random selection of
chronic infections acquired by horizontal transmission from
the Search Interface of the HIV Sequence Database (contr.2)
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage
.html). In accord with the proportions of subtype A (5 out of 7)
andC (2 out of 7) in our group of TM and children, percentages
of individuals positive for glycosylation site N295 or N339 in
the groups C2, C3, TM2, NTM, contr.1, and contr.2 were
adjusted and the results analyzed using The Supervised
Comparison of Subsets.35 p-values < 0.05 were considered
statistically significant.
Results
High viral loads and low CD4 + T cell counts
were not the only determinants for HIV-1 transmission
Viral loads and CD4+ T cell counts were measured and
compared for the 23 NTM versus seven TM (Table 1) (Fig. 1).
Four mothers gave birth to HIV-1-positive children as deter-
mined by positive HIV-1 RT-PCR reactions. This indicates three
of 26mothers (11.5%)were infected either intrapartumorduring
early breastfeeding, fitting with known HIV-1 transmission
rates when mothers are given nevirapine at time of delivery.36
The TMwere not found exclusively in the groupwith high viral
loads and low CD4+ T cell counts. Three out of the seven TM
hadCD4+ cell counts >500 cells/ll, and three of seven hadviral
loads lower than 10,000 copies/ml, with one mother in both
categories. These data suggest that factors other than viral load
and CD4+ cell counts can influence HIV-1 transmission.
Phylogenetic analyses of sequences of mothers
and children
The V1-V5 region of the gp120 envelopes of NTM and TM
was sequenced. Out of the seven TM two (29%) were infected
with subtype C viruses while five (71%) were infected with
subtype A viruses. Of the group of 23 NTM, six (26%) were
infected with subtype C and 15 (65%) with subtype A viruses
and for two mothers the virus subtype was undetermined.
We cloned and sequenced the V1-V5 regions of eight NTM
and seven TM and their infected children. Phylogenetic
analysis of the sequences of the V1-V5 regions of mothers and
children confirmed the relatedness of the virus circulating in
the respective mother–child pairs (data not shown). Four of
the seven children were infected in utero of whom child 091
Table 1. Characteristics of Transmitting Mothers, NonTransmitting Mothers, and Children
Mothers Children
Subject
TM/
NTM Subtype
Viral load day 0
RNA cies/ml
CD4 count day
0 cells/ml Subject PCR day 0
Viral load week
16 RNA cies/ml
90 TM A 203,333 250 91 Pos. 750,000
100 TM A 355,714 275 101 Pos. sna
130 TM C 85,173 595 131 Neg. 7,590
250 TM C 3,214 206 251 Pos. 269,000
290 TM A 1,018 1168 291 Pos. 531,000
300 TM A 12,104 770 301 Neg. 747,000
370 TM A 8,803 289 371 Neg. 144,000
50 NTM A 12,703 258 — — —
60 NTM A 11,463 434 — — —
110 NTM A 8,329 990 — — —
160 NTM A 396,915 164 — — —
190 NTM C 1,900 342 — — —
200 NTM A 17,213 370 — — —
340 NTM A 6,827 546 — — —
380 NTM A 4,339 602 — — —
TM, transmitting mothers; NTM, nontransmitting mothers who have been studied in detail.
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demonstrated two separate variants (Fig. 2A). All other in-
fected children had only one HIV-1 variant while the viral
quasispecies from the TM contained multiple variants (Fig.
2B). The intrapatient mean genetic distances of the V1-V5
region were analyzed (Fig. 3A). The mean genetic distance in
NTMwas 0.022 (95% CI 0.007–0.037; n= 8) and was similar to
that of TM [0.025 (95%CI 0.004–0.046; n = 6)] ( p = 0.82) or from
the children [0.007 (95 CI 0.003–0.012; n = 6)] ( p= 0.12); how-
ever, the mean intrapatient diversity in the children was sig-
nificantly lower than in the TM ( p = 0.007), which was in
NTM TM
0
500
1000
1500
CD
4 
Co
u
n
ts
 
(ce
lls
/u
l)
NTM TM
100
1000
10000
100000
1000000
Pl
as
m
a 
Vi
ra
l L
oa
d 
(R
NA
 
ci
es
/m
l)
BA
FIG. 1. Comparison of CD4 T cell counts
and viral loads in transmitting mothers
(TM) and nontransmitting mothers
(NTM). The CD4 T cell counts in cells/ll
(A) and the viral loads in number of cop-
ies/ml (B) from NTM and TM are not
significantly different. p-values were cal-
culated using the Mann–Whitney test. The
horizontal lines indicate the median for
each set.
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FIG. 2. Phylogenetic analysis of V1-V5 envelope sequences. The unrooted neighbor-joining trees show sequences of seven
mother–child pairs. (A) Sequences of day of birth of four mother–child pairs of which the children tested positive at day of
birth. (B) Sequences of 16 weeks after birth of three mother–child pairs of which the children tested negative at the day of
birth, but positive at week 16. In one case transmission of two variants occurred (pair 090/091) and in the six other cases a
single variant was transmitted. Mother’s sequences are depicted with open circles and children’s sequences with closed
circles. Bootstrap values higher than 85 are indicated with an asterisk.
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agreement with the transmission of one virus variant in six
out of seven children and two variants from one child.
V3 regions with a PNGS on position AA301
and a charge of +3 or + 4 are transmitted
We next analyzed the number of PNGS and the overall V3
charge in the three groups. PNGS-N301 (HXB2 numbering),
which is associated with CCR5 usage, was found in the ma-
jority of clones from TM (100% in 6/7 and 90% in 1/7) and
NTM (100% in 6/8, 25% and 0% in 1/8), and was present in
100% of the clones of all children. The mean V3 charges of
viruses from NTM varied between 1.89 and 4.03 (average
3.17) and for TMbetween 2.58 and 5.00 (average 3.69) andwas
found to be narrower at between 3.00 and 3.91 (average 3.40)
in the children (Fig. 3B).
No differences in V1-V2 and V1-V5 length and number
of PNGS
To identify differences between the virus variants in the
NTM and TM of children we analyzed the envelope
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FIG. 2. (Continued).
FIG. 3. Viral characteristics between
NTM, TM, and children. (A) The mean
intrapatient diversity of the V1-V5 enve-
lope region in the children (C) was sig-
nificantly lower than in TM, but not
significantly different from the NTM.
p-values were calculated using the Mann–
Whitney test. The horizontal lines repre-
sent the mean and the standard error of
the mean. (B) The mean net charges of the
V3 loop were not significantly different
between NTM, TM, and children (C), but
the range of the mean V3 charges of
viruses from children was narrower than
in the mothers. The horizontal lines rep-
resent the mean and the standard error of
the mean. p-values were calculated using
the Mann–Whitney test.
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sequences. We compared the size and the number of PNGS of
the V1-V5 region and the V1-V2 region. The mean length of
the V1-V5 region of amplified products from the NTM was
342.1 (95% CI 336.6–347.5) amino acids, in the TM 342.3 (95%
CI 337.0–347.5) amino acids ( p= 0.95), and in the children
340.0 (95% CI 334.8–345.1) ( p= 0.70) amino acids (Fig. 4A).
The mean number of PNGS in the V1V5 region of the viruses
in the NTM was 22.0 (95% CI 20.5–23.6), in the TM 22.2 (95%
CI 20.6–23.7) ( p = 1.00), and in the children 23.0 (95% CI 21.2–
24.8) ( p= 0.39) (Fig. 4B). The mean size of the V1-V2 of NTM
was 73.0 (95% CI 66.4–79.7) amino acids, in the TM 68.8 (95%
CI 64.9–72.8) ( p = 0.24) and in the children 68.6 (95% CI 64.5–
72.7) ( p = 0.22). Overall, we did not find significant differences
between the NTM, the TM, or the children in length and
number of PNGS in either the V1-V2 or V1-V5 envelope
regions.
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FIG. 4. V1-V5 envelope length and
number of potential N-glycosylation sites
(PNGS) in NTM, TM, and children. No
significant differences in V1-V5 length
(A) and number of PNGS (B) between
NTM, TM, and children (C) are observed.
p-values were calculated using the Mann–
Whitney test. The horizontal lines repre-
sent the mean and the standard error of
the mean.
Table 2. Variation in HIV-1 gp160 Potential N-Glycosylation Sites Between Nontransmitting
Mothers, Transmitting Mothers, and Children
Region HXB2pos. C2 PNGS-N234 C2-V3 PNGS-N295 C3 PNGS-N339
Children
Patient no. Subtype # clones % # clones % # clones %
91 A 12/12 100 12/12 100 12/12 100
101 A 15/15 100 0/15 0 15/15 100
131 C 12/12 100 0/12 0 12/12 100
251 C 11/11 100 11/11 100 11/11 100
291 A 12/12 100 12/12 100 12/12 100
301 A 10/10 100 10/10 100 10/10 100
371 A 10/10 100 0/10 0 0/10 0
Transmitting Mothers
Patient no. Subtype # clones % # clones % # clones %
90 A 8/8 100 8/8 100 8/8 100
100 A 6/6 100 0/6 0 6/6 100
130 C 14/14 100 0/14 0 9/14 64
250 C 8/8 100 8/8 100 1/8 13
290 A 6/10 60 10/10 100 8/10 80
300 A 11/11 100 9/11 82 11/11 100
370 A 10/10 100 0/10 0 0/10 0
Nontransmitting Mothers
Patient no. Subtype # clones % # clones % # clones %
50 A 6/6 100 6/6 100 0/6 0
60 A 16/16 100 16/16 100 7/16 44
110 A 9/9 100 9/9 100 8/9 89
160 A 12/12 100 12/12 100 3/12 25
190 C 0/11 0 11/11 100 11/11 100
200 A 0/8 0 8/8 100 0/8 0
340 A 0/19 0 19/19 100 0/19 0
380 A 12/12 100 12/12 100 0/12 0
# clones, number of clones with a PNGS/number sequenced.
PNGS, potential N-glycosylation sites.
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Selective transmission of viruses with a PNGS
on N234 and N339
To further identify envelope PNGS differences we mapped
the sites in NTM, TM, and children. Six PNGS were found
conserved in all variants for all groups (HXB2 numberingN136,
N156, N198, N262, N332, andN447), with three sites showing a
difference between the groups (Table 2). PNGS-N234 (in C2)
was present in all of the children’s clones, in the majority of the
clones of TM (86%), and less abundant in the NTM (62%). Only
60% of the clones of TM 290 had a PNGS at position N234,
whereas 100% of her child’s (291) clones possessed this PNGS,
suggesting an advantage in transmission. PNGS-N295 (be-
tween C2 and V3) was present in all NTM clones, the majority
of clones in four/seven TM, and in four/seven children, which
would suggest a disadvantage for transmission; however,
when the PNGS is present transmission can occur. Six of seven
children demonstrated PNGS-N339 in all virus variants, which
was present in themajority of clones from TM (five/seven) and
was found in only two/eight NTM. PNGS-N339 was absent in
all the clones of mother 370 and the corresponding child 371.
Only 13% of the clones of mother 250 held PNGS-N339,
whereas her child (251) had 100% of viruses carrying this
PNGS. The above findings suggest that variants with PNGS-
N234 and/or PNGS-N339 were preferentially transmitted and
that variants with PNGS-N295 had a disadvantage.
To verify our above findings we compared our results with
data from different sources (Search Interface of the HIV Se-
quence Database) where we could compare sequences of
subtype A or C viruses from children infected in utero (C2/
N = 40), from children infected through breastfeeding (C3/
N = 40), as well as frommothers who transmitted the virus by
breastfeeding (TM2/N = 83). Data from the virus populations
of NTM were not available in the database. We performed a
direct sequence analysis of 10 additional NTM fromour cohort
to increase the overall study group size. Viral sequences from
acute infection (AI) patients of subtype A andCwere included
to verify if this PNGS is associated with recently sexual
intercourse-transmitted viruses (control 1/N= 90). We also
included a random selection of sequences from drug-naive
African individuals of subtype A and C (control 2/N= 318) to
verify the prevalence of the PNGS at position 295 and 339 in
individuals other than mothers or children (Fig. 5A and B,
respectively). If more than one sequence of an individual was
available we calculated the consensus of these sequences. We
matched the percentages of individuals positive for the PNGS
to equivalent proportions of subtype A and C in the groups of
TM and children that we investigated (C1 and TM1). To de-
termine significance we performed a Supervised Comparison
of the Subjects with the children groups C1, C2, and C3 as the
reference group for the G standard (Fig. 5).
Due to the fact that sequences of groups C2, C3, and TM2
did not encompass PNGS-N234 we could not analyze this
PNGS. When analyzing further PNGS-N295 we found it to be
present in 50–70% children (C1, C2, C3), which was signifi-
cantly reduced when compared to TM2 (70%) and the acute
horizontal transmissions (control 1) (69%) (both p= 0.001),
which is in concordance with a disadvantage in MTCT for
envelopes carrying PNGS-N295 (Fig. 5A). For PNGS-N339we
found this site to be present in over 79–86% of the consensus
sequences for both TM and children, whereas for NTM and
control 1 and control 2 the frequency was significantly re-
duced (43%) ( p £ 0.001), 44% ( p£ 0.001) and 51% ( p£ 0.001),
respectively, indicating a strong positive selection in MTCT
for virus variants with a PNGS on position AA339 in the C3
region of the viral envelope (Fig. 5B).
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FIG. 5. PNGS percentages at positions (A) AA295 and (B) AA339 (HXB2 numbering). The subtype A and subtype C
sequences from our TM and children were compared to an equivalent proportion of subtype A and subtype C viruses from
the literature. C1, children infected in uterine, perinatal, or by breastfeeding. C2, children infected in uterine. C3, children
infected by breastfeeding. TM1, in uterine, perinatal, or by breastfeeding TM. TM2, by breastfeeding TM. NTM, non-
transmitting mothers. Contr.1, acute horizontal infections. Contr.2, random selection of chronic infections acquired by hor-
izontal transmission. The data for C1, TM1, and NTM are from our cohort; the data for C2, C3, TM2, Contr.1, and Contr.2 are
from the Search Interface of the HIV Sequence Database. p-values were calculated using The Supervised Comparison of
Subsets35 with the children groups C1, C2, and C3 used as the reference group for the G standard.
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Discussion
From our V1-V5 gp120 sequence analysis of viruses pref-
erentially transmitted between mothers and their children
and in comparison to nontransmitting viruses we identified a
higher frequency of PNGS at positions AA234 andAA339 and
a lower frequency of PNGS at position AA295 in transmitted
viruses. We confirmed the results of preferential transmission
of viruses with PNGS at position N339 and the disadvantage
in transmission for viruses with PNGS-N295 in MTCT
through analyzing additional cohorts of MTCT as well as in
individuals in their acute infection period and infected
through sexual intercourse. We should emphasize that for
PNGS-295 the observation is more group based than at the
individual transmission pair level.
In sexual transmission HIV-1 subtype A and C variants
with shorter envelope and fewer PNGS have been shown to
be more efficiently transmitted and more susceptible to neu-
tralizing antibodies present within the donor.37–39 One report
concludes that variants transmitted from mother to child did
not have shorter V1-V5 regions but did have fewer PNGS,11
while another study showed no association between trans-
mitted variants and the length of the variable loops or the
number of PNGS.40 We did not find differences in the number
and the length of the V1-V2 and the V1-V5 regions between
NTM, TM, and children in our cohort. Probably resistant
viruses are preferentially transmitted from mother to child
but it is not clear how changes in length of the envelope and in
the number of PNGS correlate with MTCT.11,12,37,41,42
A low overall net charge and a PNGS at N301 within the
gp120 V3 variable loop have been heavily associated with
CCR5 usage.7 In agreement with other reports that show se-
lection of CCR5 using variants in transmission we found that
all transmitted viruses contained PNGS-N301 and that the V3
charge of these viruses was restricted to + 3 and + 4, although
the viruses of both mothers’ groups had V3 charges ranging
from + 2 to + 5. The majority of studies to date have reported
on viruses with low V3 charges being preferentially trans-
mitted and here we describe a narrow range in V3 charges
within children even when mothers contain quasispecies of
viruses with lower charges. This could result from such
viruses being the major variants in the TM, but could also
reflect a less stable electrostatic interaction between gp120 and
the array of receptors to which it binds and which may in-
fluence HIV-1 transmission, including CD4, CCR5, or DC-
SIGN.39,43 PNGSN197, N230, N241, N301, N332, N386, N392,
and N397 (HXB2 numbering) have been identified as candi-
dates to play a role in DC-SIGN binding and may therefore
exert such an influence through modulating this specific in-
teraction.44,45
The selection for viruses with PNGS-N339 in viruses un-
dergoing MTCT and not in acute horizontal infections could
be explained by neutralizing antibody selection. Children will
possess antibodies from the mothers whereas individuals
sexually exposed to HIV-1 will not have such antibodies and
can therefore be infected with viruses lacking PNGS-N339.
The function of PNGS-N339 in the envelope of the children
remains to be determined; however, PNGS-N339 is situated in
the a2-helix region of C3 and several reports have demon-
strated that residues within the a2-helix of subtype C viruses
are under strong positive selection and that unique mutational
patterns in the a2-helix and acquisition of length in gp120 hy-
pervariable domains are associated with resistance to autolo-
gous neutralization of HIV-1 subtype C.46 The disadvantage in
MTCT for PNGS-N295 can be explained by the generation of
resistance against neutralizing antibodies similar to 2G12.47
The further clarification of mechanisms of HIV-1 MTCT
and the viruses involved will provide insights into which
gp120 envelope regions may need to be targeted in a vaccine
aimed at restricting transmission. Therapeutic vaccination of
HIV-1-positive mothers during their pregnancy against such
variants may have the benefit of restricting MTCT during all
possible transmission periods and allow for lower rates of
infection. We demonstrate that PNGS-N234 and PNGS-N339
within the gp120 envelope is associated with the risk of viral
transmission from mother to child. Knowledge concerning
which viruses are preferentially transmitted may aide in the
future design of HIV-1 vaccine immunogens aimed at re-
stricting MTCT.
Acknowledgments
The authors would like to thank the participants for their
study involvement and Dr. J.M. Ruijter for assistance with the
statistical analysis.
Accession numbers
GenBank accession numbers JN187678–JN187853 and
JN097489–JN097554.
Author Disclosure Statement
No competing financial interests exist.
References
1. Kourtis AP, Lee FK, Abrams EJ, et al.: Mother-to-child
transmission of HIV-1: Timing and implications for pre-
vention. Lancet Infect Dis 2006;6(11):726–732.
2. Ometto L, Zanchetta M, Mainardi M, et al.: Co-receptor
usage of HIV-1 primary isolates, viral burden, and CCR5
genotype in mother-to-child HIV-1 transmission. AIDS 2000;
14(12):1721–1729.
3. Clevestig P, Maljkovic I, Casper C, et al.: The X4 phenotype
of HIV type 1 evolves from R5 in two children of mothers,
carrying X4, and is not linked to transmission. AIDS Res
Hum Retroviruses 2005;21(5):371–378.
4. Reinhardt PP, Reinhardt B, Lathey JL, and Spector SA: Hu-
man cord blood mononuclear cells are preferentially infected
by non-syncytium-inducing, macrophage-tropic human im-
munodeficiency virus type 1 isolates. J Clin Microbiol 1995;
33(2):292–297.
5. Shalekoff S, Gray GE, and Tiemessen CT: Age-related
changes in expression of CXCR4 and CCR5 on peripheral
blood leukocytes from uninfected infants born to human
immunodeficiency virus type 1-infected mothers. Clin Diagn
Lab Immunol 2004;11(1):229–234.
6. de Jong JJ, de RA, Keulen W, Tersmette M, and Goudsmit J:
Minimal requirements for the human immunodeficiency
virus type 1 V3 domain to support the syncytium-inducing
phenotype: Analysis by single amino acid substitution. J
Virol 1992;66(11):6777–6780.
7. Hartley O, Klasse PJ, Sattentau QJ, and Moore JP: V3: HIV’s
switch-hitter. AIDS Res Hum Retroviruses 2005;21(2):171–
189.
722 BAAN ET AL.
8. Pollakis G, Abebe A, Kliphuis A, et al.: Phenotypic and ge-
notypic comparisons of CCR5- and CXCR4-tropic human
immunodeficiency virus type 1 biological clones isolated
from subtype C-infected individuals. J Virol 2004;78(6):2841–
2852.
9. Matala E, Hahn T, Yedavalli VR, and Ahmad N:
Biological characterization of HIV type 1 envelope V3 re-
gions from mothers and infants associated with perinatal
transmission. AIDS Res Hum Retroviruses 2001;17(18):
1725–1735.
10. Rainwater SM, Wu X, Nduati R, et al.: Cloning and charac-
terization of functional subtype A HIV-1 envelope variants
transmitted through breastfeeding. Curr HIV Res 2007;5(2):
189–197.
11. Wu X, Parast AB, Richardson BA, et al.: Neutralization es-
cape variants of human immunodeficiency virus type 1 are
transmitted from mother to infant. J Virol 2006;80(2):835–
844.
12. Blish CA, Blay WM, Haigwood NL, and Overbaugh J:
Transmission of HIV-1 in the face of neutralizing antibodies.
Curr HIV Res 2007;5(6):578–587.
13. Dickover R, Garratty E, Yusim K, et al.: Role of maternal
autologous neutralizing antibody in selective perinatal
transmission of human immunodeficiency virus type 1 es-
cape variants. J Virol 2006;80(13):6525–6533.
14. Rong R, Bibollet-Ruche F, Mulenga J, et al.: Role of V1V2 and
other human immunodeficiency virus type 1 envelope do-
mains in resistance to autologous neutralization during
clade C infection. J Virol 2007;81(3):1350–1359.
15. Pancera M, Majeed S, Ban YE, et al.: Structure of HIV-1
gp120 with gp41-interactive region reveals layered envelope
architecture and basis of conformational mobility. Proc Natl
Acad Sci USA 2010;107(3):1166–1171.
16. Chackerian B, Rudensey LM, and Overbaugh J: Specific N-
linked and O-linked glycosylation modifications in the en-
velope V1 domain of simian immunodeficiency virus vari-
ants that evolve in the host alter recognition by neutralizing
antibodies. J Virol 1997;71(10):7719–7727.
17. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV
gp120 envelope glycoprotein in complex with the CD4 re-
ceptor and a neutralizing human antibody. Nature 1998;
393(6686):648–659.
18. Pinter A, Honnen WJ, He Y, et al.: The V1/V2 domain of
gp120 is a global regulator of the sensitivity of primary
human immunodeficiency virus type 1 isolates to neutrali-
zation by antibodies commonly induced upon infection. J
Virol 2004;78(10):5205–5215.
19. Sagar M, Wu X, Lee S, and Overbaugh J: Human immuno-
deficiency virus type 1 V1-V2 envelope loop sequences ex-
pand and add glycosylation sites over the course of
infection, and these modifications affect antibody neutrali-
zation sensitivity. J Virol 2006;80(19):9586–9598.
20. Wyatt R, Moore J, Accola M, et al.: Involvement of the V1/
V2 variable loop structure in the exposure of human im-
munodeficiency virus type 1 gp120 epitopes induced by
receptor binding. J Virol 1995;69(9):5723–5733.
21. Gray ES, Moore PL, Choge IA, et al.: Neutralizing antibody
responses in acute human immunodeficiency virus type 1
subtype C infection. J Virol 2007;81(12):6187–6196.
22. Geijtenbeek TBH, Kwon DS, Torensma R, et al.: DC-SIGN, a
dendritic cell specific HIV-1-binding protein that enhances
trans-infection of T cells. Cell 2000;100(5):587–597.
23. Haase AT: Perils at mucosal front lines for HIV and SIV and
their hosts. Nat Rev Immunol 2005;5(10):783–792.
24. Hladik F and McElrath MJ: Setting the stage: host invasion
by HIV. Nat Rev Immunol 2008;8(6):447–457.
25. Rappocciolo G, Piazza P, Fuller CL, et al.: DC-SIGN on B
lymphocytes is required for transmission of HIV-1 to T
lymphocytes. PLoS Pathog 2006;2(7):e70.
26. Luchters SMF, Veldhuijzen NJ, Nsanzabera D, et al.: A phase
I/II, randomized, placebo controlled study to evaluate
chloroquine administration for reduction of HIV-1 RNA in
breast milk in an HIV-infected breastfeeding population,
The CHARGE study. XV International AIDS Conference,
11–16 July 2004, Bangkok, Thailand, PeB4499.
27. Boom R, Sol CJ, Salimans MM, et al.: Rapid and simple
method for purification of nucleic acids. J Clin Microbiol
1990;28(3):495–503.
28. Pollakis G, Kang S, Kliphuis A, et al.: N-linked glycosylation
of the HIV type-1 gp120 envelope glycoprotein as a major
determinant of CCR5 and CXCR4 coreceptor utilization. J
Biol Chem 2001;276(16):13433–13441.
29. Renjifo B, Chung M, Gilbert P, et al.: In-utero transmission of
quasispecies among human immunodeficiency virus type 1
genotypes. Virology 2003;307(2):278–282.
30. Renjifo B, Fawzi W, Mwakagile D, et al.: Differences in
perinatal transmission among human immunodeficiency
virus type 1 genotypes. J Hum Virol 2001;4(1):16–25.
31. Koulinska IN, Villamor E, Msamanga G, et al.: Risk of HIV-1
transmission by breastfeeding among mothers infected with
recombinant and non-recombinant HIV-1 genotypes. Virus
Res 2006;120(1–2):191–198.
32. Salazar-Gonzalez JF, Bailes E, Pham KT, et al.: Deciphering
human immunodeficiency virus type 1 transmission and
early envelope diversification by single-genome amplifica-
tion and sequencing. J Virol 2008;82(8):3952–3970.
33. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al.: In-
flammatory genital infections mitigate a severe genetic bot-
tleneck in heterosexual transmission of subtype A and C
HIV-1. PLoS Pathog 2009;5(1):e1000274.
34. Abrahams MR, Anderson JA, Giorgi EE, et al.: Quantitating
the multiplicity of infection with human immunodeficiency
virus type 1 subtype C reveals a non-poisson distribution of
transmitted variants. J Virol 2009;83(8):3556–3567.
35. Schaaf GJ, Ruijter JM, van RF, et al.: Full transcriptome
analysis of rhabdomyosarcoma, normal, and fetal skeletal
muscle: Statistical comparison of multiple SAGE libraries.
FASEB J 2005;19(3):404–406.
36. Ayouba A, Tene G, Cunin P, et al.: Low rate of mother-to-
child transmission of HIV-1 after nevirapine intervention in
a pilot public health program in Yaounde, Cameroon. J
Acquir Immune Defic Syndr 2003;34(3):274–280.
37. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al.: Envelope-
constrained neutralization-sensitive HIV-1 after heterosex-
ual transmission. Science 2004;303(5666):2019–2022.
38. Chohan B, Lang D, Sagar M, et al.: Selection for human
immunodeficiency virus type 1 envelope glycosylation var-
iants with shorter V1-V2 loop sequences occurs during
transmission of certain genetic subtypes and may impact
viral RNA levels. J Virol 2005;79(10):6528–6531.
39. KeeleBFandDerdeynCA:Geneticandantigenic features of the
transmitted virus. Curr Opinion HIV AIDS 2009;4(5):352–357.
40. Samleerat T, Braibant M, Jourdain G, et al.: Characteristics of
HIV type 1 (HIV-1) glycoprotein 120 env sequences in
mother-infant pairs infected with HIV-1 subtype CRF01_AE.
J Infect Dis 2008;198(6):868–876.
41. Rong R, Li B, Lynch RM, et al.: Escape from autologous
neutralizing antibodies in acute/early subtype C HIV-1
HIV-1 gp120 GLYCOSYLATION LINKED WITH MTCT 723
infection requires multiple pathways. PLoS Pathog
2009;5(9):e1000594.
42. Moore PL, Ranchobe N, Lambson BE, et al.: Limited neu-
tralizing antibody specificities drive neutralization escape in
early HIV-1 subtype C infection. PLoS Pathog 2009;5(9):
e1000598.
43. Margolis L and Shattock R: Selective transmission of CCR5-
utilizing HIV-1: The ’gatekeeper’ problem resolved? Nat Rev
Micro 2006;4(4):312–317.
44. Hong PWP, Nguyen S, Young S, et al.: Identification of the
optimal DC-SIGN binding site on human immunodeficiency
virus type 1 gp120. J Virol 2007;81(15):8325–8336.
45. Hong PW, Flummerfelt KB, de PA, et al.: Human immuno-
deficiency virus envelope (gp120) binding to DC-SIGN and
primary dendritic cells is carbohydrate dependent but does
not involve 2G12 or cyanovirin binding sites: Implications
for structural analyses of gp120-DC-SIGN binding. J Virol
2002;76(24):12855–12865.
46. Rong R, Gnanakaran S, Decker JM, et al.: Unique mutational
patterns in the envelope alpha 2 amphipathic helix and ac-
quisition of length in gp120 hypervariable domains are as-
sociated with resistance to autologous neutralization of
subtype C human immunodeficiency virus type 1. J Virol
2007;81(11):5658–5668.
47. Gray ES, Moore PL, Pantophlet RA, and Morris L: N-linked
glycan modifications in gp120 of human immunodeficiency
virus type 1 subtype C render partial sensitivity to 2G12 an-
tibody neutralization. J Virol 2007;81(19):10769–10776.
Address correspondence to:
William A. Paxton
K3-106
Laboratory of Experimental Virology
Academic Medical Center
University of Amsterdam
Meibergdreef 15
Amsterdam, 1105AZ
The Netherlands
E-mail: w.a.paxton@amc.uva.nl
724 BAAN ET AL.
